NAFLD: An Emerging Causal Factor for Cardiovascular Disease

被引:19
作者
Li, Mei [1 ]
Wang, Hongmin [2 ]
Zhang, Xiao-Jing [1 ,3 ,4 ]
Cai, Jingjing [3 ,5 ]
Li, Hongliang [1 ,3 ,4 ]
机构
[1] Wuhan Univ, Sch Basic Med Sci, Wuhan, Peoples R China
[2] Huanggang Cent Hosp, Dept Rehabil Med, Huanggang, Peoples R China
[3] Wuhan Univ, Inst Model Anim, Wuhan, Peoples R China
[4] Wuhan Univ, Dept Cardiol, Renmin Hosp, Wuhan, Peoples R China
[5] Cent South Univ, Xiangya Hosp 3, Dept Cardiol, Changsha, Peoples R China
关键词
atherosclerosis; cardiovascular disease; endothelial dysfunction; heart failure; NAFLD; FATTY LIVER-DISEASE; RENIN-ANGIOTENSIN SYSTEM; PLACEBO-CONTROLLED TRIAL; GLP-1 RECEPTOR AGONISTS; INSULIN-RESISTANCE; TISSUE FACTOR; FACTOR VIIA; RISK; PROGRESSION; MECHANISMS;
D O I
10.1152/physiol.00013.2023
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide that poses a significant threat to human health. Cardiovascular disease (CVD) is the leading cause of mortality in NAFLD patients. NAFLD and CVD share risk factors such as obesity, insulin resistance, and type 2 diabetes. However, whether NAFLD is a causal risk factor for CVD remains a matter of debate. This review summarizes the evidence from prospective clinical and Mendelian randomization studies that underscore the potential causal relationship between NAFLD and CVD. The mechanisms of NAFLD contributing to the development of CVD and the necessity of addressing CVD risk while managing NAFLD in clinical practice are also discussed.
引用
收藏
页码:255 / 265
页数:11
相关论文
共 126 条
[1]   Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases [J].
Adams, Leon A. ;
Anstee, Quentin M. ;
Tilg, Herbert ;
Targher, Giovanni .
GUT, 2017, 66 (06) :1138-1153
[2]   Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis [J].
Aithal, Guruprasad P. ;
Thomas, James A. ;
Kaye, Philip V. ;
Lawson, Adam ;
Ryder, Stephen D. ;
Spendlove, Ian ;
Austin, Andrew S. ;
Freeman, Jan G. ;
Morgan, Linda ;
Weeber, Jonathan .
GASTROENTEROLOGY, 2008, 135 (04) :1176-1184
[3]   Triglyceride Metabolism in the Liver [J].
Alves-Bezerra, Michele ;
Cohen, David E. .
COMPREHENSIVE PHYSIOLOGY, 2018, 8 (01) :1-22
[4]   Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].
Armstrong, Matthew James ;
Gaunt, Piers ;
Aithal, Guruprasad P. ;
Barton, Darren ;
Hull, Diana ;
Parker, Richard ;
Hazlehurst, Jonathan M. ;
Guo, Kathy ;
Abouda, George ;
Aldersley, Mark A. ;
Stocken, Deborah ;
Gough, Stephen C. ;
Tomlinson, Jeremy W. ;
Brown, Rachel M. ;
Huebscher, Stefan G. ;
Newsome, Philip N. .
LANCET, 2016, 387 (10019) :679-690
[5]   The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a banier-protective response in endothelial cells [J].
Bae, Jong-Sup ;
Yang, Likui ;
Manithody, Chandrashekhara ;
Rezaie, Alireza R. .
BLOOD, 2007, 110 (12) :3909-3916
[6]   Regulation of Apolipoprotein B by Natural Products and Nutraceuticals: A Comprehensive Review [J].
Bagherniya, Mohammad ;
Johnston, Thomas P. ;
Sahebkar, Amirhossein .
CURRENT MEDICINAL CHEMISTRY, 2021, 28 (07) :1363-1406
[7]   Overview of Epidemiology and Contribution of Obesity to Cardiovascular Disease [J].
Bastien, Marjorie ;
Poirier, Paul ;
Lemieux, Isabelle ;
Despres, Jean-Pierre .
PROGRESS IN CARDIOVASCULAR DISEASES, 2014, 56 (04) :369-381
[8]   A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].
Belfort, Renata ;
Harrison, Stephen A. ;
Brown, Kenneth ;
Darland, Celia ;
Finch, Joan ;
Hardies, Jean ;
Balas, Bogdan ;
Gastaldelli, Amalia ;
Tio, Fermin ;
Pulcini, Joseph ;
Berria, Rachele ;
Ma, Jennie Z. ;
Dwivedi, Sunil ;
Havranek, Russell ;
Fincke, Chris ;
DeFronzo, Ralph ;
Bannayan, George A. ;
Schenker, Steven ;
Cusi, Kenneth .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307
[9]   Metabolic drivers of non-alcoholic fatty liver disease [J].
Bence, Kendra K. ;
Birnbaum, Morris J. .
MOLECULAR METABOLISM, 2020, 50
[10]   Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and Coronary Artery Disease [J].
Brouwers, Martijn C. G. J. ;
Simons, Nynke ;
Stehouwer, Coen D. A. ;
Koek, Ger H. ;
Schaper, Nicolaas C. ;
Isaacs, Aaron .
HEPATOLOGY COMMUNICATIONS, 2019, 3 (04) :587-596